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Structured Abstract: 39 
Objective: Fontan circulatory inefficiency can be addressed by replacing the missing 40 
subpulmonary power source to reverse the Fontan paradox. An implantable cavopulmonary 41 
assist device is described that will simultaneously reduce systemic venous pressure and increase 42 
pulmonary arterial pressure, thereby improving preload and cardiac output, in a univentricular 43 
Fontan circulation on a long-term basis. 44 
Methods: A rotary blood pump based on the von Karman viscous pump was designed for 45 
implantation into the total cavopulmonary connection (TCPC). It will impart modest pressure 46 
energy to augment Fontan flow without risk of obstruction. In the event of rotational failure, it is 47 
designed to default to a passive flow diverter. Pressure-flow (H-Q) performance was 48 
characterized in vitro in a Fontan mock circulatory loop using blood analog. 49 
Results: The pump performed through the fully specified operating range, augmenting flow in 50 
all 4 directions of the TCPC. Pressure rise of 6-8 mmHg was readily achieved, ranging up to 14 51 
mmHg at highest speed (5600 RPM). Performance was consistent over a wide range of cardiac 52 
output. In the stalled condition (0 RPM), there was no discernible pressure loss across the TCPC. 53 
Conclusions: A blood pump technology is described that can reverse the Fontan paradox and 54 
may permit a surgical strategy of long-term biventricular maintenance of a univentricular Fontan 55 
circulation. The technology is intended for Fontan failure in which right-sided circulatory 56 
inefficiencies predominate and ventricular systolic function is preserved. It may also apply prior 57 
to clinical Fontan failure as health maintenance to preempt the progression of Fontan disease. 58 
Abstract word count: 249/250 59 
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Central Message: An implantable blood pump that can safely and reliably reverse the Fontan 60 
paradox long-term may enable a physiologically curative strategy for single ventricle heart 61 
disease. (Characters including spaces: 174/200) 62 
 63 
Perspective Statement: Fontan palliation is associated with a chronic circulatory inefficiency 64 
that culminates in secondary disease, failure, and attrition. We report feasibility of an 65 
implantable cavopulmonary assist device that can safely replace the missing subpulmonary 66 
power source and reverse the Fontan paradox long-term. This may enable a physiologically 67 
curative strategy for single functional ventricle. (characters including spaces: 390/405) 68 
 69 
Central picture Legend: Cavopulmonary assist device: flow augmentation through the total 70 
cavopulmonary connection. (Characters including spaces: 90/90) 71 
 72 
Glossary of Abbreviations 73 
MCS, mechanical circulatory support 74 
TCPC, total cavopulmonary connection 75 
SVC, superior vena cava 76 
IVC, inferior vena cava 77 
RPA, right pulmonary artery 78 
LPA, left pulmonary artery 79 
VAD, ventricular assist device 80 
5 
 
Repair of single functional ventricle currently consists of staged surgical approach that 81 
terminates in a univentricular Fontan circulation. Since its introduction, Fontan palliation has 82 
dramatically improved the outcome for all forms of single ventricle heart disease [1,2]. However, 83 
Fontan survivors are committed for the remainder of their lives to a state of chronic circulatory 84 
inefficiency due to the lack of a subpulmonary ventricle. 85 
This results in coexisting elevated systemic venous pressure and reduced cardiac output, 86 
known clinically as the Fontan paradox [3]. Combined, these problems have been clearly shown 87 
to progress to late Fontan failure and attrition [4]. Despite extensive clinical and research effort, 88 
therapies to prevent or reverse this circulatory decline remain extremely limited with no 89 
breakthroughs for decades [5]. With an increasing number of late Fontan survivors, Fontan 90 
failure is now a routinely encountered and challenging clinical problem. 91 
We have theorized that replacement of the missing subpulmonary power source would 92 
reverse the Fontan paradox and shift the univentricular circulation toward more stable 93 
biventricular equivalency [6]. It would decongest the systemic venous and lymphatic 94 
circulations, while simultaneously improving cardiac output. If applied as durable long-term 95 
support, it could in theory preempt Fontan-associated disease progression by maintaining 96 
biventricular equivalency. 97 
Despite the simplicity and attractiveness of this concept, the technologic considerations 98 
are complex and dissimilar to any other mechanical circulatory support (MCS) application. We 99 
have found that existing MCS technologies are ill-suited and unmodifiable to address Fontan 100 
circulatory inefficiency. Alternatively, we have focused on the development of an anatomically-101 
specific device that can replace the missing subpulmonary power source and reverse the Fontan 102 
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paradox [7]. This report describes the computational and in vitro basis for an implantable 103 
cavopulmonary assist device concept that has potential to safely and durably restore biventricular 104 
equivalency in a univentricular circulation. 105 
 106 
Methods: 107 
Pump design: In previous studies, we have demonstrated that a remotely powered rotary 108 
pump, based on the von Karman viscous pump, can provide 4-way flow augmentation through 109 
the total cavopulmonary connection (TCPC) [7]. A biconical impeller suspended in the midst of 110 
the TCPC functions as a 2-sided centrifugal pump, drawing inflow from the superior and inferior 111 
vena cavae (SVC, IVC), and augmenting outflow to the left and right pulmonary arteries (LPA, 112 
RPA) at physiologic pressure. A modest pressure step-up of 6 mmHg has been shown in vitro 113 
and in vivo to restore the univentricular Fontan circulation to biventricular equivalency under 114 
normal physiologic conditions [6,7]. We have also demonstrated that a cavopulmonary assist 115 
device based on the von Karman viscous pump will not obstruct the systemic venous pathway in 116 
the event of rotational dysfunction, and will instead reduce kinetic energy loss in the TCPC [7]. 117 
Because an external power source would limit such a device to temporary use, a 118 
permanent power source was incorporated in the form of an outrunner brushless DC (BLDC) 119 
motor. In an outrunner motor, the rotating component is outside rather than inside (Figure 1). For 120 
an in-series pump situated in the Fontan venous pathway, this configuration is key to eliminating 121 
the risk of venous pathway obstruction because it allows preservation of a wide passage between 122 
the impeller and housing. As a result, the pump can serve in 2 distinctly different capacities: 123 
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rotating, it functions as a pump; non-rotating, it functions as a static flow diverter (Figure 2). 124 
Thus, it is intended to be beneficial even if it fails. 125 
A biconical stator, containing iron laminations and copper windings, is located centrally 126 
within the impeller, and has no blood contact or moving parts. It is surrounded by a biconical 127 
rotor with embedded magnets as the only moving component. Rotor surface vanes provide low-128 
pressure, high-volume augmentation of cavopulmonary flow (Video 1). A secondary (internal) 129 
flow path between the rotor and the stator is an inherent centrifugal pump and integrates several 130 
key functions: 1) electromagnetic flux transfer for motor torque; 2) heat dissipation; 3) bearing 131 
lubrication; 4) rotordynamic stabilization (Video 2). The housing is a double inlet, double outlet 132 
thin-walled hardcase shell that serves only to direct TCPC flow and structurally suspend the 133 
pump. Wiring from the stator travels through the central shaft to exit the housing via shaft struts. 134 
Because there is no external component bulk, the pump is no larger than the native TCPC, and is 135 
suitable for in situ implantation. 136 
An advanced prototype was designed and fabricated at adult scale (25 mm dia inlets, 20 137 
mm dia outlets) (Figure 3). Using computational fluid dynamic (CFD) modeling, impeller 138 
dimension and motor size were determined based on the torque required to achieve a pressure 139 
rise of 6-8 mmHg under physiologic conditions. Non-circumferential conical bearings support 140 
the rotor at each end. The impeller surface vane height is only 0.7 mm. The pump was tested 141 
initially in an open circuit, with no baseline imposed flow, using blood analog (water/glycerin 142 
63/37, physiologic density 1060 kg/m3, 3.2 cP). Testing was then performed in a static loop for 143 
pressure-flow (H-Q) performance, and lastly in vitro in a mock loop of a Fontan circulation for 144 
physiologic performance. For static performance, the pump was operated at 0-5600 RPM against 145 
5 different resistances. Steady-state pressure head and flow rates were plotted to characterize 146 
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hydraulic (H-Q) performance. Inlet partial and complete occlusion performance was assessed. 147 
For physiologic performance testing, a Fontan mock circulatory system was utilized that includes 148 
compliance and resistance elements [7]. 149 
 150 
Results: 151 
All design objectives were met, including: 1) pressure-flow performance of 0-14 mmHg 152 
pressure rise over 0-5600 RPM; 2) mean scalar shear stress < 100 Pa, transit time < 0.01s; 3) 153 
non-cavitating performance; 4) acceptable recirculation; 5) no pressure loss in the static 154 
condition (0 RPM). Heat dissipation was excellent, confirmed by reduction of core temperature 155 
at higher speed. Hydraulic performance was consistent over a wide range of cardiac output 156 
(Figure 4). A peak pressure of 14 mmHg was achieved at the highest speed. The pump generated 157 
5 L/min of flow and 6 mmHg pressure head at 4000 RPM, and 5 L/min of flow and 8 mmHg 158 
pressure head at 5600 RPM. The in-vitro pump performance was consistent with the design 159 
specifications and CFD modeling (6-8 mmHg pressure rise under physiologic conditions). The 160 
pump generated inflow from both the SVC and IVC equally to both pulmonary arteries for 161 
SVC:IVC inflow ratios ranging from 30:70 to 50:50. The pump effectively mixed inflow from 162 
both inlets with symmetric outflow distribution (hepatic factor, Video 1).  The power draw was 163 
less than 6W at maximal speed, and is expected to improve with further optimization. Because 164 
the surface vane profile is so low, there is flexibility to increase vane height for higher pressure 165 
performance without compromising the no-obstruction constraint. 166 
In in vitro physiologic mock loop testing, the device effectively reversed the Fontan 167 
(Figure 5). With increasing RPM, ventricular end-diastolic pressure and aortic pressure 168 
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increased. At 5000 RPM, the pump converted a cavopulmonary pressure head of positive 2.8 169 
mmHg to negative 4.8 mmHg, replacing a small energy loss with a proportionally larger gain.  It 170 
boosted pulmonary arterial pressure by 6 mmHg, and increased preload sufficient to increase 171 
cardiac output by 12.8%.  Vena caval pressure was reduced 1.4 mmHg, which is significant in 172 
this segment of the circulation where even small reduction of pressure is beneficial to splanchnic 173 
health. Increase in pump speed beyond 5000 RPM caused a larger negative cavopulmonary 174 
pressure head but did not lead to a measurable increase cardiac output. When the pump was 175 
stopped (0 RPM), there was no discernible pressure drop, validating the no-obstruction design 176 
constraint. Importantly, in the stopped condition, TCPC turbulence was reduced compared to the 177 
condition with no pump installed. 178 
 179 
Discussion: 180 
Amongst the many significant advances in the treatment of congenital heart disease over 181 
the past 5 decades, single ventricle palliation has had perhaps the largest impact. Nonetheless, it 182 
was predicted by its’ innovators that it may be incompatible with a normal lifespan and require 183 
improvement or modification [9-11]. As predicted, Fontan-associated disease now represents one 184 
of the most significant challenges in the field. Although Fontan palliation is lifesaving, it carries 185 
a lifelong chronic disease burden that has no primary preventive therapy and is ultimately life-186 
limiting [12,13]. As a reflection of its palliative nature, late Fontan attrition is relatively constant 187 
suggesting that immutable factors play a role, and 30-year survival is only 43-70% [14-16]. 188 
 Solutions to address Fontan-associated disease have been largely incremental and of 189 
unclear benefit, and we may have reached a plateau. Fontan optimization can at best only 190 
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prolong an inherently inefficient system because it does not address the underlying physiologic 191 
deficit: the lack of a subpulmonary ventricle. To date, little effort has focused on mechanical 192 
replacement of a subpulmonary power source, presumably because a comprehensive solution is 193 
unobvious and highly complex. However, replacement of the missing subpulmonary power 194 
source is physiologically compelling: it will normalize systemic venous pressure, decongest the 195 
lymphatic circulation, and normalize ventricular loading conditions, emulating biventricular 196 
efficiency. Given the ongoing problems with Fontan-associated disease, it is reasonable to 197 
reconsider the current paradigm. Rather than Fontan perpetuation, a preferable strategy may be 198 
to reverse the Fontan [17]. 199 
 200 
Fontan failure is largely non-ventricular failure: Although those with failing Fontan 201 
circulations may exhibit classic features of congestive heart failure, the primary cause is not 202 
typically ventricular systolic dysfunction. Prior to end-stage Fontan disease, ejection fraction is 203 
preserved in >70% of patients; diastolic dysfunction predominates [18]. While the mechanisms 204 
are complex and multi-factorial, Fontan diastolic dysfunction has been largely attributed to 205 
chronic preload deprivation [19,20]. Over time, abnormal loading conditions (decreased preload, 206 
increased afterload) result in cardiomyopathic remodeling and fibrosis [21], and eventual systolic 207 
dysfunction. Thus, it can be said that the Fontan circulation predisposes the single ventricle to 208 
fail. Furthermore, efforts that target improvement in ventricular function as a solution to Fontan 209 
disease may be misguided; it may be of greater benefit to provide cavopulmonary assistance. 210 
Cavopulmonary assist specifically addresses the lack of a subpulmonary power source, 211 
and will in turn normalize ventricular loading conditions and improve function. In the setting of 212 
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diastolic dysfunction but preserved systolic function, a modest increase in preload (~1-3 mmHg) 213 
will improve myocardial performance and cardiac output (opposite primary myocardial failure). 214 
Transplantation is, in a sense, a definitive therapy for Fontan failure in that it reinstates a 215 
subpulmonary ventricle, but it does so at the cost of a different disease process. There aren’t 216 
sufficient donor organs available to transplant all single ventricle patients. Due to listing criteria, 217 
most Fontan patients won’t receive a donor organ until they have end-stage disease with 218 
advanced co-morbidities. Transplant survival of <50% at 10 years is arguably no better than the 219 
natural history of late Fontan attrition [22]. For these reasons, transplantation is not a 220 
comprehensive solution and represents end-stage therapy. 221 
 222 
Fontan optimization falls short: Strategies to optimize Fontan hemodynamics have 223 
logically targeted the TCPC, where anatomic factors may result in significant power loss [23-224 
25]. These have included various vena caval offset configurations, as well as a Fontan ‘Y’ 225 
conduit to reduce power loss in the inferior vena caval distribution [26]. Although these 226 
modifications have been applied clinically, they have not had significant impact. The maximal 227 
pressure gain that can be derived from passive flow optimization (~1-2 mmHg) does not fully 228 
correct the circulatory deficit and, as a result, does not meaningfully improve circulatory status. 229 
By comparison, consider normal biventricular physiology in which the right ventricle provides a 230 
cavopulmonary pressure step-up of ~6-8 mmHg. To make a clinically meaningful improvement 231 
in Fontan, it is necessary to add pressure energy at the TCPC by a similar amount. 232 
 233 
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Limitations of current MCS technology applied to Fontan: The application of existing 234 
MCS devices for Fontan failure is limited, highly variable, and associated with poor outcomes 235 
[27-30]. It has generally focused on the application of systemic support in end-stage Fontan 236 
disease due to the nature of existing technologies. Nearly all MCS technologies are intended for 237 
systemic support. However, depending on the circumstances, the device is likely mismatched to 238 
Fontan circulatory needs, i.e. left-sided support to address a right-sided deficit. Anecdotally, 239 
existing MCS appears to be better suited for ventricular “pump” failure in Fontan, rather than for 240 
Fontan failure secondary to lack of a subpulmonary ventricle. In the setting of preserved systolic 241 
function, systemic MCS in Fontan is redundant; it may needlessly congest the right-sided 242 
circulation where the circulatory bottleneck exists and exacerbate Fontan disease. 243 
Existing MCS applied strategically to the right side of the Fontan circulation has been 244 
reported [31]; however, it is logistically impractical for several reasons: 1) the Fontan must be 245 
taken down to accommodate a single inflow, single outflow device; 2) a systemic MCS device is 246 
not optimized to the very low pressure rise desired for cavopulmonary assist, increasing risk for 247 
device failure; 3) the right-sided circulation is dependent on the device, making device 248 
dysfunction lethal; 4) device operational lifespan is limited, and therefore not a long-term 249 
solution. Given these considerations, the use of existing MCS technology in Fontan is limited to 250 
end-stage disease as bridge therapy, if it is used at all. 251 
 252 
Technical considerations for long-term Fontan reversal: Dedicated right-sided circulatory 253 
support of the Fontan circulation presents a number of caveats that are uniquely challenging 254 
(Table 1). Technically, a cavopulmonary assist device is not a ventricular assist device (VAD) 255 
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because it provides support where no ventricle exists. It is intended to function as a low-input 256 
auxiliary right-sided pump to maintain low systemic venous pressure and preload to the systemic 257 
ventricle, identical to the essential function of the right ventricle in a biventricular circulation 258 
[32]. 259 
Although comparatively a weak pump, the inherent performance a von Karman viscous 260 
pump is ideal for the Fontan circulation. As a dynamic pump, it can provide consistent pressure 261 
rise over a wide range of cardiac output, making it responsive to physiologic demand. Low 262 
hydraulic efficiency also makes it less likely to generate suction, vein collapse, and cavitation, 263 
and tolerant to physiologic variation in systemic venous return. Similarly, it is unlikely to 264 
generate excessive downstream pressure, reducing risk for lung perfusion injury. The majority of 265 
existing MCS devices are displacement pumps that must vary RPM to vary flow rate, making 266 
them susceptible to suction, and unresponsive to physiologic demand thereby limiting exercise 267 
capacity. 268 
The TCPC is the best-known geometry for passive cavopulmonary flow [23]. Thus, our 269 
strategy has been to retain the TCPC as a default flow path, and design an anatomically-specific 270 
pump to add pressure energy within it. A central diverting body at the TCPC intersection will 271 
split incoming flow toward each outlet, significantly reducing turbulent energy loss [33,34]. By 272 
rotating a central stabilizing body, suspended within the TCPC independent of the vessel walls, 273 
fluid pressure and velocity is increased, transforming it from a static flow diverter to a pump. We 274 
also anticipate that a permanently implanted device will eventually fail. In Fontan, a pump 275 
situated in the center of the flow path cannot impede flow (Figure 6). This is a critical safety 276 
consideration in young Fontan patients with decades of life expectancy ahead of them. 277 
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The ideal pressure rise for a cavopulmonary assist device is not yet clinically determined. We 278 
have shown in this study, and in other in vitro mock circulatory studies of a Fontan circulation 279 
that 6 mmHg pressure step-up will restore biventricular equivalency under normal physiologic 280 
conditions [7,8]. This pressure rise correlates with normal circulatory physiology. The presence 281 
of increased pulmonary vascular resistance in Fontan may impact the magnitude of pressure rise 282 
required. Extremely elevated pulmonary resistance is incompatible with late Fontan survival; 283 
therefore, we believe the need for a pressure increase significantly greater than ~15 mmHg is 284 
unlikely. Further, in the cavopulmonary circulation, the margin to apply an aggressive pressure 285 
step-up is limited by baseline systemic venous pressure. For example, the application of a 20 286 
mmHg pressure step-up in the TCPC in which baseline systemic venous pressure is 16 mmHg 287 
will induce negative (-4 mmHg) systemic venous pressure, leading to suction collapse and flow 288 
disruption. 289 
In general, MCS devices are not placed in line or in series with the circulation, but are rather 290 
placed in parallel (i.e. paracardiac) due to risk of device obstruction of the native flow path. This 291 
concern is amplified for a Fontan pump situated in the lowest pressure segment of the 292 
circulation, where seemingly trivial obstruction can induce hemodynamic instability. An 293 
implantable Fontan pump must have no potential for mechanical obstruction in the event of 294 
dysfunction. 295 
 296 
Emerging technologies: Single functional ventricle is a final frontier for MCS therapy, and 297 
concepts for dedicated Fontan circulatory support are currently evolving [8,35]. To date, nearly 298 
all have focused on modification of existing technology (unidirectional axial or centrifugal 299 
VADs) to operate in the low-pressure Fontan environment. Although these may suffice as bridge 300 
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therapy, they lack the technologic rigor required for safe and durable long-term support. They are 301 
incapable of supporting flow in all 4 limbs of the cavopulmonary connection, and will induce 302 
back-pressure elevation in the opposing systemic venous territory. They are capable of 303 
mechanical obstruction, a prohibitive issue when the right-sided circulation is dependent on the 304 
device. Due to motor configuration, they may be bulky and not fit within the confines of the 305 
TCPC. Lastly, if the Fontan pathway is modified to accommodate a unidirectional flow device, 306 
the resulting pathway will not support passive cavopulmonary flow in the event of device 307 
dysfunction. With respect to safety and durability, a Fontan pump that offers multi-directional 308 
flow, in situ anatomic placement, and a contingency plan for failure is preferable. 309 
 310 
Clinical implications: Cavopulmonary assist reframes single ventricle palliation from a 311 
problem with no solution to a problem with an obvious solution. The challenge lies in creating a 312 
technology that can safely and durably implement it. If successfully translated, it would represent 313 
a first-ever targeted therapy for Fontan failure. It would also permit biventricular equivalency to 314 
be maintained in a univentricular circulation prior to clinical failure, preempting Fontan disease. 315 
For Fontan patients who have few options to alter their inevitable disease progression, this 316 
concept has exciting potential to shift the paradigm for single ventricle therapy from palliation to 317 
cure. 318 
The clinical vision for a Fontan-specific cavopulmonary assist device is much different from 319 
current MCS strategy. Rather than reserving MCS for end-stage salvage, it may be better to 320 
apply it preemptively for biventricular health maintenance. Thus, the device may not necessarily 321 
be limited to advanced Fontan failure, and may be considered earlier. For Fontan patients, the 322 
implications are starkly different: a lifetime of chronic disease progression with systemic MCS 323 
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as end-stage therapy versus cavopulmonary assist to enable long-term biventricular health and 324 
wellness, potentially for decades. 325 
 326 
Limitations: This report presents early stage electromechanical feasibility for an 327 
implantable cavopulmonary assist device concept. Such a therapy has never been implemented 328 
clinically; therefore, discussion of clinical application and duration of support is theoretical. 329 
Substantial technologic development remains to be performed, and significant obstacles may 330 
arise in future design iteration. Thrombogenicity performance remains to be determined, and 331 
device durability is unknown. The power source has not yet been determined, although it is 332 
envisioned to be powered wirelessly. Until a device is fully developed, regulatory approved, and 333 
enters clinical trial, the translational impact of long-term Fontan reversal will remain speculative.  334 
 335 
Conclusions: After Fontan repair of single functional ventricle, patients are trapped for 336 
the remainder of their lives in a cycle of chronic circulatory inefficiency. Despite dramatic 337 
improvement in surgical technique, perioperative care, and long-term surveillance, late Fontan 338 
failure and attrition remains an intractable problem for which there is no primary or preventive 339 
therapy. An early stage implantable cavopulmonary assist device shows promising potential to 340 
reverse the Fontan paradox and preempt Fontan-associated disease as a curative therapy. It 341 
represents a significant opportunity to fundamentally shift the paradigm for single ventricle care 342 
to one based on biventricular health. 343 
 344 
 345 
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 347 
Table 1. Desirable technical features for a long-term cavopulmonary assist device: 348 
1. Simplicity. A single pump, with one moving part, that serves as a low-input 349 
primer for the systemic ventricle. 350 
2. Multi-directional flow. Flow augmentation in all 4 distributions of the TCPC 351 
(SVC/IVC inflow, RPA/LPA outflow). 352 
3. Low pressure performance. Low pressure (~6-8 mmHg), high volume flow 353 
augmentation, similar to normal right ventricular hemodynamics.  354 
4. Wide performance range. Consistent pressure rise over a wide range of cardiac 355 
output and variable physiologic demand, independent of pump speed. 356 
5. Unobstructive. An in-line pump in the Fontan venous pathway must account for 357 
pump failure, with minimal or no obstruction risk as a failure default. 358 
6. TCPC as the preferred default flowpath. The failed (0 RPM) condition should 359 
ideally optimize passive TCPC flow as an unsupported Fontan circulation. 360 
7. Permissive preload and afterload performance. Low hydraulic efficiency to reduce 361 
risk of excessive negative upstream pressure (suction, vein collapse, cavitation), 362 
and excessive positive downstream pressure (perfusion lung injury). It will also 363 
permit tolerance to the natural inflow instabilities that occur in systemic venous 364 
return (supine vs upright posture, cough, Valsalva). 365 
8. Mixing. Symmetric hepatic factor distribution to prevent pulmonary arteriovenous 366 
malformation (Video 1). 367 
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9. No barrier to recirculation. To reduce thrombogenicity and obstruction risk. 368 
10. Small size. In situ implantation to avoid physical encroachment on adjacent 369 
structures (e.g. aorta, common atrium, pulmonary veins). 370 
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 479 
 480 
Figure Legend: 481 
Figure 1: Outrunner brushless DC motor: A. Traditional motor design with inner rotating 482 
component. B. Outrunner motor design with outer rotating component and stationary central 483 
component. 484 
Figure 2: Implantable cavopulmonary assist device concept. A central impeller contains the 485 
motor (impeller support shaft and struts not shown). The external housing is a hard case, 486 
thin-walled shell that has no component bulk and serves only to direct Fontan flow. The wide 487 
gap between the impeller and the housing must support passive TCPC flow in the event of 488 
device dysfunction. 489 
Figure 3: Advanced prototype, adult scale. A: Design schematic showing housing with 490 
mounted impeller. Wiring travels from the stator via the central shaft and strut to exit the 491 
housing. The only moving component is the rotor. A secondary flow path allows for inflow 492 
at each axial end, with outflow at the equatorial gap (Video 2). B: Design schematic showing 493 
patulous channel to prevent obstruction in the event of rotational failure. Rotor surface shows 494 
0.7 mm height curved surface vanes. C: Assembled prototype as tested and demonstrated in 495 
video. 496 
Figure 4: Hydraulic performance. H-Q curve demonstrates pressure and flow performance. 497 
Figure 5: In vitro mock loop parameter showing reversal of the failing Fontan circulation 498 
with cavopulmonary assist. Fontan baseline includes pump in TCPC in stalled condition. 499 
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VIP, viscous impeller pump; HR, heart rate; SV, stroke volume; CO, cardiac output; CO% 500 
increase, percent increase from baseline Fontan cardiac output; VCP, vena caval pressure; 501 
PAP, pulmonary artery pressure; CPPH, cavopulmonary pressure head (pump ∆P) = vena 502 
caval pressure – pulmonary artery pressure; AoP, aortic pressure. 503 
Figure 6: Pump implantation (conceptual). The cavopulmonary assist device is implanted in 504 
situ in the TCPC and serves to modestly augment cavopulmonary flow. The device is 505 
compatible with either lateral tunnel and extracardiac conduit Fontan construction. Graft 506 
extensions allow for suturing, with a total of 4 anastomoses. Grafts can be extended or 507 
tailored to address anatomic issues. Two pumps are depicted. The systemic ventricle 508 
performs the majority work load. It is served by a low-input cavopulmonary assist device to 509 
normalize preload to the systemic ventricle, in addition to reducing systemic venous pressure. 510 
(TCPC: total cavopulmonary connection; SVC: superior vena cava; IVC: inferior vena cava; 511 
PA: pulmonary artery) 512 
 513 
 514 
Video legend: 515 
 Video 1: Primary (external) flow path. Open static circuit; flow is induced by the pump. 516 
Yellow and blue contrast represent systemic venous inflow. The green outflow represents left 517 
and right pulmonary arterial flow. Mixing indicates symmetric hepatic factor distribution. 518 
 519 
 Video 2: Secondary (internal) flow path. Open static circuit; flow is induced by the pump. 520 
Contrast injection flows selectively through the internal flow path, with dispersion of outflow at 521 
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the equatorial midline. Internal path flow is essential to pump function for heat dissipation, 522 
bearing flushing, and to reduce risk of recirculation, stasis, and thrombosis. 523 
Case VIP 
Speed 
(RPM) 
HR 
(beats/min) 
CO 
(L/min) 
CO % 
increase 
VCP 
(mmHg) 
PAP 
(mmHg) 
CPPH 
(mmHg) 
AoP 
(mmHg) 
Fontan 
Baseline 
0 75 3.9 - 17.5 14.7 2.8 98.3/57.4 
Fontan 
+ VIP 
3000 75 4.1 5.1% 17 16.6 0.4 102.3/60.5 
Fontan 
+ VIP 
4000 75 4.3 10.3% 16.8 18 -1.2 111.9/66.7 
Fontan 
+ VIP 
5000 75 4.4 12.8% 16.1 20.8 -4.8 113.6/69.0 
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